Exploring Nintedanib and Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis

Opinion
Video

An expert discusses how nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating idiopathic pulmonary fibrosis (IPF).

Video content above is prompted by the following:

How do nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating IPF?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
1 expert in this video
1 expert in this video
© 2025 MJH Life Sciences

All rights reserved.